Friday, November 11, 2016

BRIEF-Idera reports data from ongoing Phase 1 clinical trial of intratumoral IMO-2125

* Idera Pharmaceuticals reports translational data

supporting the mechanism of action of intratumoral IMO-2125 from

ongoing Phase 1 dose escalation in clinical trial in combination

with ipilimumab in...

Read more

No comments:

Post a Comment